Noema Pharma
noemapharma.com
Actively hiring
Rare Disease Therapeutics
Neurology & CNS Therapeutics
Drug Discovery
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$115.4M
2 rounds on record
Latest round
Series B
Nov 2024 · 23 mo ago
Team
11-50
employees, estimated range
Hiring now
1
open roles
Backers
2
Jeito Capital, Sofinnova Partners
The money's age
Due for its next round
23 months since the last round · hiring slowed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 8, 2025
New executive Noema Pharma Appoints Michael Samar as Chief Financial Officer · noemapharma.com
Nov 12, 2024
Raised a round Series B · FinanzNachrichten.de
Nov 14, 2023
New executive Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer · kdvr.com
Mar 6, 2023
Raised a round Series B $115.4M
2019
Founded
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Nov 2024 | — | Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris | FinanzNachrichten.de |
| Series B | Mar 2023 | $115.4M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Jeito Capital 
Sofinnova Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high…
Draupnir Bio is developing new innovative therapies for patients.
AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or…
0 Enable better lives through novel therapies to restore skeletal muscle health About NMD Pharma NMD Pharma is a clinical-stage biotech…
Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading…
Applied Cognition is a platform therapeutic company developing drugs to enhance brain glymphatic function and treat Alzheimer’s disease.
Overview
Noema Pharma is a biotech company developing therapies for the most disabling symptoms of orphan conditions of the brain and nervous system. Its research and development focuses on understanding and meeting patient needs across orphan and broader neurology indications, and it hires a director of regulatory affairs. The company is headquartered in Basel, Switzerland.
News
Noema Pharma to Present Phase 2a Results for Cendifensine in Vasomotor Symptoms (Hot Flashes) Due to Menopause at the 2026 ACOG Annual Clinical & Scientific Meeting
Read more
Report
Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
Cendifensine demonstrates 92% reduction in number of hot flashesBASEL, Switzerland and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopaus
Read more
Report
Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
Cendifensine demonstrates 92% reduction in number of hot flashes Basel, Switzerland and Boston, MA - November 6, 2025 - Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopausal women
Read more
Report
Noema Pharma Appoints Michael Samar as Chief Financial Officer
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development BASEL, Switzerland, January 8, 2025 (GLOBE NEWSWIRE) - Noema Pharma, a clinical-stage biotech company tar
Read more
Report
Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) - Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Volker Knappertz, M.D., as Executive Vice President of Re
Read more
Report
Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
EQT Life Sciences expands the Series B with additional capital, alongside continued support from existing investors, including, Forbion, Jeito Capital, Sofi ...
Read more
Report
EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million
/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma ("the Company"). The clinical-stage biotech company...
Read more
Report
Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million)
EQT Life Sciences expands the Series B with additional capital, alongside continued support from existing investors, including, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris
Read more
Report
Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome
- Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome - BASEL, Switzerland, Oct. 30, 2024 - Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have
Read more
Report
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
- Topline results from Phase 2a study - Nearly 60% of all patients treated with gemlapodect and 88% of patients completing the study at the target clinical dose range were responders based on the primary efficacy assessment The Yale Global Tics Severity S
Read more
Report
Show more news
Growth
Hiring Momentum
21/100
Hiring freeze
Open positions
1
0 opened / 0 closed in 30 days
Median time-to-fill
188 days
faster than 8% of the market
ATS activity
Every ~8 hours
10/19/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Public Policy
100% ▼
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Basel
Switzerland
HQ
10-50 est. staff